Equities

Stille AB

STIL:STO

Stille AB

Actions
  • Price (SEK)205.00
  • Today's Change-2.00 / -0.97%
  • Shares traded1.02k
  • 1 Year change+93.40%
  • Beta1.0537
Data delayed at least 15 minutes, as of Nov 22 2024 13:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Stille AB is a Sweden-based company engaged in the development, manufacture, and marketing of technical medical equipment. The product portfolio is divided into two business lines. The Surgery business area develops, produces and markets handcrafted, forged surgical instruments for all fields of open surgery, with an emphasis on cardiovascular surgery, and reconstructive and aesthetic plastic surgery. Its products include scissors, forceps, artery forceps, needle holders and clamps, among others. The Patient Positioning area develops and manufactures two main groups of procedure-specific specialized tables for cardiovascular surgery and gynecology, urology and urodynamic examinations. As of December 31, 2011, the Company had two wholly owned subsidiaries, Stille Surgical Inc. and Stille Incentive AB. As of December 30, 2011, the it's largest shareholder was Linc Invest AB (39.81%). On September 2, 2013, the Company sold its business unit, Sonesta, to ADDvise Lab Solutions publ AB.

  • Revenue in SEK (TTM)487.43m
  • Net income in SEK50.86m
  • Incorporated1984
  • Employees151.00
  • Location
    Stille ABEkbacken 11TORSHAELLA 644 30SwedenSWE
  • Phone+46 858858000
  • Fax+46 858858005
  • Websitehttps://www.stille.se/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
STIL:STO since
announced
Transaction
value
Fehling Instruments Gmbh & Co. KgAnnounced29 Nov 202329 Nov 2023Announced95.24%--
Data delayed at least 15 minutes, as of Nov 22 2024 13:31 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bactiguard Holding AB254.96m-56.11m1.07bn163.00--3.67--4.19-1.60-1.607.289.370.37063.847.601,174,917.00-8.16-7.56-11.32-8.8147.5347.91-22.01-26.280.5898-2.720.4175---11.966.46-161.71--8.43--
BioPorto A/S54.22m-95.22m1.12bn36.00--8.26--20.62-0.163-0.1630.09390.20140.33763.396.121,126,000.00-59.29-71.10-74.24-96.5570.6263.38-175.62-239.224.91-52.720.0507--6.873.5425.81---51.56--
Paxman AB (publ)238.86m28.64m1.20bn102.0041.918.2125.525.011.501.5012.547.671.312.746.562,624,791.0015.66-5.0820.74-7.7670.2769.3811.99-5.071.9812.730.0838--43.9929.35180.69--6.26--
Sedana Medical AB (publ)174.14m-57.24m1.22bn78.00--1.28--6.99-0.5763-0.57631.759.560.16971.1610.142,204,317.00-5.58-5.77-5.84-6.0870.6064.06-32.87-36.136.02-30.480.0076--25.2321.5918.90--42.12--
Nordhealth As506.12m-95.70m1.68bn403.00--3.3257.593.32-1.23-1.236.5011.210.475--9.491,282,595.00-8.98---10.01--85.89---18.91------0.00--18.60--21.96------
Genovis AB129.73m27.91m1.78bn32.0063.808.0145.4613.730.42630.42631.983.390.4239----3,506,189.009.1218.569.8021.4564.6965.5121.5123.88----0.25550.0054.5435.56449.56--47.59--
Stille AB487.43m50.86m1.86bn151.0032.712.7724.803.826.336.3360.9474.850.69782.108.494,598,368.007.287.038.708.1949.1743.9310.439.851.127.410.0021.9819.7016.78-2.485.3423.62--
Detection Technology Oyj-1.16tn-1.16tn2.36bn464.00--2.76----------5.03----------9.34--11.96--47.44--8.223.39--0.0053.455.292.027.55-18.03-14.88-9.55
BICO Group AB2.25bn-786.80m2.39bn828.00--0.8285--1.06-11.15-15.2031.9241.790.36022.154.472,547,964.00-12.62---14.44--55.70---35.03--2.23-0.57050.397--6.09---1,889.33------
Medistim ASA546.54m101.54m2.58bn152.0025.416.3720.424.735.555.5529.8722.121.130.74617.483,599,204.0021.0522.9325.5328.5279.1278.2518.5820.642.75--0.018175.257.0010.06-8.9112.720.03314.87
Data as of Nov 22 2024. Currency figures normalised to Stille AB's reporting currency: Swedish Krona SEK

Institutional shareholders

25.90%Per cent of shares held by top holders
HolderShares% Held
Healthinvest Partners ABas of 31 Aug 2023460.00k5.12%
Lannebo Fonder ABas of 31 Aug 2023445.88k4.96%
SEB Investment Management ABas of 31 Aug 2023392.20k4.37%
Aktia Bank Plc (Investment Management)as of 31 Oct 2024380.35k4.23%
Aktia Fondbolag Abas of 31 Aug 2023220.00k2.45%
Fondita Fund Management Co. Ltd.as of 30 Sep 2024180.00k2.00%
Enter Fonder ABas of 30 Jun 202489.88k1.00%
ODIN Forvaltning AS (Sweden)as of 28 Jun 202467.00k0.75%
Schroder Investment Management Ltd.as of 31 Dec 202360.00k0.67%
Amundi Asset Management SA (Investment Management)as of 30 Sep 202431.80k0.35%
More ▼
Data from 30 Jun 2024 - 13 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.